Therapeutics Articles
Grifols’ higher-potency rabies immune globulin (RIG), HyperRAB S/D, was made available to healthcare providers
Discontinuation of the product is due to the preference among healthcare professionals and patients for newer, more advanced immune globulin options.
The U.S. Food and Drug Administration has approved Shire’s VONVENDI, a recombinant von Willebrand factor treatment for perioperative management of bleeding in adults 18 years and older with von Willebrand disease.
Researchers have found antibiotics can be counterproductive and weaken the immune system’s ability to fight off bacteria.
A multidisciplinary team of investigators based in New Delhi randomized 120 patients with liver cirrhosis and overt hepatic encephalopathy (HE) to receive oral lactulose therapy or oral lactulose plus 1.5 g/kg/day of human albumin. The primary study endpoint was complete reversal of HE; secondary endpoints included mortality and length of hospital stay.
Australian investigators tested the ability of intravenous immune globulin to protect against potential pandemic influenza virus in outbred ferrets, which are naturally susceptible to human influenza viruses and considered a relevant small animal model of human influenza infection.
